Acute Hepatic Injury Associated with Acute Administration of Synthetic Cannabinoid XLR-11 in Mouse Animal Model
暂无分享,去创建一个
Dima Albals | G. Abdelhady | Malek Shehab | M. A. Zoubi | M. I. AbuAlarjah | Hiba Alzoubi | Bahaa Al-Trad | W. El‐Huneidi | Ayman Alzu'bi | M. Zoubi
[1] Qing-Rong Liu,et al. Hepatocyte cannabinoid 1 receptor nullification alleviates toxin-induced liver damage via NF-κB signaling , 2020, Cell Death & Disease.
[2] A. Koçyiğit,et al. Investigation of DNA damage, oxidative stress, and inflammation in synthetic cannabinoid users , 2020, Human & experimental toxicology.
[3] G. Özhan,et al. Inflammation and oxidative stress are key mediators in AKB48-induced neurotoxicity in vitro. , 2019, Toxicology in vitro : an international journal published in association with BIBRA.
[4] M. A. Zaman,et al. Acute Liver Injury Induced by Synthetic Cannabinoid Abuse , 2018, Cureus.
[5] T. Roušar,et al. An overview of apoptosis assays detecting DNA fragmentation , 2018, Molecular Biology Reports.
[6] F. Carvalho,et al. The synthetic cannabinoid XLR-11 induces in vitro nephrotoxicity by impairment of endocannabinoid-mediated regulation of mitochondrial function homeostasis and triggering of apoptosis. , 2018, Toxicology letters.
[7] J. Ladero,et al. Liver fibrosis. , 2018, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.
[8] P. Jordan,et al. Synthetic Cannabinoid Abuse and a Rare Alpha-1-Antitrypsin Mutant Causing Acute Fulminant Hepatitis: A Case Report and Review of the Literature , 2017, Case reports in hepatology.
[9] G. Martinotti,et al. Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset. , 2017, CNS & neurological disorders drug targets.
[10] U. Lindequist,et al. Mitochondrial functions of THP-1 monocytes following the exposure to selected natural compounds. , 2017, Toxicology.
[11] S. Ricci,et al. Hepatotoxicity associated to synthetic cannabinoids use. , 2017, European review for medical and pharmacological sciences.
[12] W. Fantegrossi,et al. Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites. , 2017, Current topics in behavioral neurosciences.
[13] A. Mehari,et al. Synthetic Marijuana-Induced Acute Liver Failure: 1820 , 2016 .
[14] Qing-Rong Liu,et al. Human CB1 Receptor Isoforms, present in Hepatocytes and β-cells, are Involved in Regulating Metabolism , 2016, Scientific Reports.
[15] L. Olsen,et al. Cytochrome P450-mediated metabolism of the synthetic cannabinoids UR-144 and XLR-11. , 2016, Drug testing and analysis.
[16] V. Angerer,et al. Genotoxic properties of XLR-11, a widely consumed synthetic cannabinoid, and of the benzoyl indole RCS-4 , 2016, Archives of Toxicology.
[17] D. Mountain,et al. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment , 2016, Clinical toxicology.
[18] A. Haslberger,et al. Impact of a synthetic cannabinoid (CP-47,497-C8) on protein expression in human cells: evidence for induction of inflammation and DNA damage , 2016, Archives of Toxicology.
[19] G. Behonick,et al. Case reports of synthetic cannabinoid XLR-11 associated fatalities. , 2015, Forensic science international.
[20] R. Law,et al. Increase in Reported Adverse Health Effects Related to Synthetic Cannabinoid Use — United States, January–May 2015 , 2015, MMWR. Morbidity and mortality weekly report.
[21] Shane M. Wilkinson,et al. Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. , 2015, ACS chemical neuroscience.
[22] S. Hudson,et al. Delayed seizure-like activity following analytically confirmed use of previously unreported synthetic cannabinoid analogues , 2015, Human & experimental toxicology.
[23] K. Kuwayama,et al. Detection of main metabolites of XLR-11 and its thermal degradation product in human hepatoma HepaRG cells and human urine. , 2015, Drug testing and analysis.
[24] C. Marescaux,et al. Tetrahydrocannabinol Induces Brain Mitochondrial Respiratory Chain Dysfunction and Increases Oxidative Stress: A Potential Mechanism Involved in Cannabis-Related Stroke , 2015, BioMed research international.
[25] Bishow Paudel,et al. Synthetic cannabinoids: the multi-organ failure and metabolic derangements associated with getting high , 2015, Journal of community hospital internal medicine perspectives.
[26] H. Yoo,et al. Determination of urinary metabolites of XLR-11 by liquid chromatography–quadrupole time-of-flight mass spectrometry , 2015, Analytical and Bioanalytical Chemistry.
[27] M. Lukšič,et al. SPICE/K2 Synthetic Marijuana-Induced Toxic Hepatitis Treated with N-Acetylcysteine , 2014, The American journal of case reports.
[28] Marilyn A Huestis,et al. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. , 2014, Drug and alcohol dependence.
[29] B. Thomas,et al. Cannabinoids in disguise: Δ9-Tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles , 2013, Neuropharmacology.
[30] Marilyn A Huestis,et al. First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. , 2013, Clinical chemistry.
[31] Y. Zou,et al. PKC&bgr; Promotes Vascular Inflammation and Acceleration of Atherosclerosis in Diabetic ApoE Null Mice , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[32] N. Teixeira,et al. Endogenous cannabinoids revisited: a biochemistry perspective. , 2013, Prostaglandins & other lipid mediators.
[33] G. Zlabinger,et al. Toxicological profiles of selected synthetic cannabinoids showing high binding affinities to the cannabinoid receptor subtype CB1 , 2013, Archives of Toxicology.
[34] P. Hollenberg,et al. Cytochrome P450-Mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in K2/Spice: Identification of Novel Cannabinoid Receptor Ligands , 2012, Drug Metabolism and Disposition.
[35] K. Heard,et al. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. , 2012, Annals of emergency medicine.
[36] T. Prisinzano,et al. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. , 2012, Biochemical pharmacology.
[37] W. Fratta,et al. Beyond THC: The New Generation of Cannabinoid Designer Drugs , 2011, Front. Behav. Neurosci..
[38] William E. Fantegrossi,et al. Phase I Hydroxylated Metabolites of the K2 Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and Activity , 2011, PloS one.
[39] B. Aggarwal,et al. Oxidative stress, inflammation, and cancer: how are they linked? , 2010, Free radical biology & medicine.
[40] R. Flisiak,et al. Role of cannabinoids in chronic liver diseases. , 2008, World journal of gastroenterology.
[41] Liying Li,et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. , 2005, Gastroenterology.
[42] R. Hampson,et al. Cannabinoid physiology and pharmacology: 30 years of progress , 2004, Neuropharmacology.
[43] A. Tarakhovsky,et al. PKCβ modulates antigen receptor signaling via regulation of Btk membrane localization , 2001, The EMBO journal.
[44] A. Makriyannis,et al. Functional CB1 cannabinoid receptors in human vascular endothelial cells. , 2000, The Biochemical journal.
[45] F. Cuccurullo,et al. TBA test and "free" MDA assay in evaluation of lipid peroxidation and oxidative stress in tissue systems. , 1993, The American journal of physiology.
[46] S. Aust,et al. Microsomal lipid peroxidation. , 1978, Methods in enzymology.